Envestnet Asset Management
TGTX icon

Envestnet Asset Management’s TG Therapeutics TGTX Stock Holding History

Envestnet Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.53M Buy
118,860
+13,029
+12% +$533K ﹤0.01% 2276
2026
Q1 		$3.52M Buy
105,831
+32,542
+44% +$970K ﹤0.01% 2597
2025
Q4 		$2.18M Buy
73,289
+19,326
+36% +$631K ﹤0.01% 2757
2025
Q3 		$1.95M Buy
53,963
+2,281
+4% +$75.1K ﹤0.01% 2896
2025
Q2 		$1.86M Buy
51,682
+1,422
+3% +$52.9K ﹤0.01% 2876
2025
Q1 		$1.98M Buy
50,260
+149
+0.3% +$5.01K ﹤0.01% 2735
2024
Q4 		$1.51M Buy
50,111
+5,135
+11% +$147K ﹤0.01% 2875
2024
Q3 		$1.05M Buy
44,976
+7,097
+19% +$155K ﹤0.01% 3110
2024
Q2 		$674K Sell
37,879
-1,002
-3% -$16K ﹤0.01% 3281
2024
Q1 		$591K Sell
38,881
-7,826
-17% -$125K ﹤0.01% 3333
2023
Q4 		$798K Buy
46,707
+5,359
+13% +$62.3K ﹤0.01% 3070
2023
Q3 		$346K Buy
41,348
+13,526
+49% +$189K ﹤0.01% 3451
2023
Q2 		$691K Buy
27,822
+11,973
+76% +$309K ﹤0.01% 3028
2023
Q1 		$238K Buy
15,849
+5,394
+52% +$81.9K ﹤0.01% 3570
2022
Q4 		$124K Buy
+10,455
New +$75.9K ﹤0.01% 3776
2021
Q4 		– Sell
-8,574
Closed -$285K – 3945
2021
Q3 		$285K Sell
8,574
-3,847
-31% -$119K ﹤0.01% 3322
2021
Q2 		$482K Buy
12,421
+1,513
+14% +$59.4K ﹤0.01% 3010
2021
Q1 		$526K Buy
10,908
+4,154
+62% +$200K ﹤0.01% 2818
2020
Q4 		$351K Buy
+6,754
New +$228K ﹤0.01% 2850

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Envestnet Asset Management's TGTX Position: Q2 2026 in Review

Envestnet Asset Management increased its TG Therapeutics (TGTX) stake by 12% in Q2 2026, buying an estimated $533K and bringing the position to 118,860 shares worth $6.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2276.

Envestnet Asset Management first reported a position in TGTX in Q4 2020 and has held it in 19 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Envestnet Asset Management held 118,860 shares of TG Therapeutics worth $6.53M as of Q2 2026.
  • Envestnet Asset Management bought 13,029 TG Therapeutics shares in Q2 2026, an estimated $533K.
  • TG Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #2276 holding.
  • Envestnet Asset Management first reported a position in TG Therapeutics in Q4 2020 and has held it in 19 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.